article thumbnail

In Brain Chemistry We Trust—The Gospel According to Pharma

Mad in America

Depression was sold to us as a simple problem of serotonin insufficiency, a convenient narrative that made drug companies like Eli Lilly, Forest Pharmaceuticals, and Pfizer very rich. As a former pharmaceutical advertising writer, I not only witnessed the explosive growth in antidepressant drugs, I contributed to it.

article thumbnail

The Psychiatric Pipeline in Review: Quarter 2, 2025

Psychiatric Times

New NDA Submitted: Bysanti to Treat Acute Bipolar I and Schizophrenia Vanda Pharmaceuticals submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) requesting marketing approval of milsaperidone (Bysanti, also known as VHX-896 and P-88) for the treatment of patients with acute bipolar I disorder and schizophrenia.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Behind the Smiles: Mental Health in South Korea’s High-Pressure Society

Mad in America

It is a reflection of deep systemic issuessocial pressure, medical hierarchy, lack of education around mental healththat collectively push people into silent suffering and pharmaceutical dependence. In a society where education is often seen as the primary vehicle for success, becoming a doctor is regarded as the ultimate achievement.

article thumbnail

June in Review: Updates on the Psychiatric Treatment Pipeline

Psychiatric Times

NRx Pharmaceuticals seeks FDA approval for NRX-100, a preservative-free ketamine for suicidal depression and PTSD, via the National Priority Voucher pathway. Ecopipam has demonstrated long-term safety and efficacy in reducing tic severity in pediatric patients with Tourette syndrome, with no tachyphylaxis observed.

article thumbnail

Tardive Dyskinesia: Treat Functional Impairment, Not the AIMS Score

Psychiatric Times

The resulting Impact-TD scale measures the degree of functional impact on 4 categories: social, psychological/psychiatric, physical, vocational/educational/recreational. Teva Pharmaceuticals; 2025. US Department of Health, Education, and Welfare; 1976:534-537. J Clin Psychiatry. 2017;78(8):1136-1147. Austedo/AustedoXR.

article thumbnail

The 2025 Summer Heatwave: Implications for Patients With Psychiatric Disorders

Psychiatric Times

Although prevention is key, Barbee said patient education should also include the signs and symptoms of heat intolerance. She has also served as advisory board participant for Supernus Pharmaceuticals and Axsome Therapeutics. Barbee also reminds patients about sweat wicking clothing and cooling accessories.

article thumbnail

Exploding Myths About Schizophrenia: An Interview with Courtenay Harding

Mad in America

It was called chlorpromazine (Thorazine) and was made from an earlier pharmaceutical in 1951 used to relax naval hospital patients getting ready for surgery. Employment depended on education primarily. At this time, across the US there was huge excitement about a drug for patients and it was being tested.